NHS Blood and Transplant is organizing a stem cell treatment protocol in Liverpool, England for patients with diabetes related kidney disease. The randomized controlled trial will compare injections of mesenchymal stem cells with placebo injections and study whether stem cells will slow down or halt tissue damage, removing the current reliance on dialysis or transplants.
The protocol described has already been utilized in animal studies, showing significant improvements in kidney function. Stem cells release proteins that reduce inflammation in the kidney. Its promise for people with diabetes is vast: roughly three in four diabetics develop some form of kidney disease. For the 48 patients under study at University Hospitals Birmingham NHS Foundation Trust, this development may signal a significant treatment breakthrough. According to Dr. Eric Austin, head of Stem Cell Immunotherapy at NHS Blood and Transplant's site in Liverpool, "This is an exciting project for us to be involved with - especially as the treatment has the potential to lead to lifesaving outcomes for a major illness."
We believe the best stem cells to use in emerging regenerative treatments will be the patient’s own stem cells as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.